Table 1 Demographic & clinical characteristics by treatment group
Variables | Chemotherapy only N = 38 | Cetuximab N = 38 | BevacizumabN = 106 | Total N = 182 |
|---|---|---|---|---|
Gender, n (%) | ||||
Female | 23 (60.5%) | 14 (36.8%) | 56 (52.8%) | 93 (51.1%) |
Age (years) | ||||
Mean (SD) | 60.8 (14.7) | 64.6 (11.2) | 61.5 (12.3) | 62.0 (12.6) |
US Region, n (%) | ||||
Northeast | 4 (10.5%) | 3 (7.9%) | 3 (2.8%) | 10 (5.5%) |
Midwest | 0 (0.0%) | 2 (5.3%) | 4 (3.8%) | 6 (3.3%) |
South | 27 (71.1%) | 28 (73.7%) | 83 (78.3%) | 138 (75.8%) |
West | 7 (18.4%) | 5 (13.2%) | 16 (15.1%) | 28 (15.4%) |
Race, n (%) | ||||
White | 26 (68.4%) | 26 (68.4%) | 71 (67.0%) | 123 (67.6%) |
Minority | 12 (31.6%) | 12 (31.6%) | 35 (33.0%) | 59 (32.4%) |
Sub-Total | 38 (100%) | 38 (100%) | 106 (100%) | 182 (100%) |
BMI | ||||
Mean (SD) | 26.3 (6.2) | 28.9 (5.2) | 26.9 (5.4) | 27.2 (5.6) |
Disease Stage, n (%) | ||||
Stage IV | 38 (100%) | 38 (100%) | 106 (100%) | 182 (100%) |
ECOG, n (%) | ||||
0 | 8 (21.1%) | 10 (26.3%) | 19 (17.9%) | 37 (20.3%) |
1 | 8 (21.1%) | 6 (15.8%) | 19 (17.9%) | 33 (18.1%) |
2+ | 2 (5.3%) | 3 (7.9%) | 3 (2.8%) | 8 (4.4%) |
Text indication of impairment | 4 (10.5%) | 2 (5.3%) | 14 (13.2%) | 20 (11.0%) |
No text indication of impairment | 16 (42.1%) | 17 (44.7%) | 51 (48.1%) | 84 (46.2%) |
Sites of Distant Metastasis, n (%) * | ||||
Liver | 24 (63.2%) | 24 (63.2%) | 71 (67.0%) | 119 (65.4%) |
Lung | 14 (36.8%) | 21 (55.3%) | 50 (47.2%) | 85 (46.7%) |
Peritoneum | 9 (23.7%) | 6 (15.8%) | 28 (26.4%) | 43 (23.6%) |
Small intestine | 0 (0%) | 0 (0%) | 4 (3.8%) | 4 (2.2%) |
Other | 16 (42.1%) | 15 (39.5%) | 47 (44.3%) | 78 (42.9%) |
Not documented | 0 (0%) | 0 (0%) | 1 (0.9%) | 1 (0.5%) |